STAT3
STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
Overview
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4.
CIViC holds 2 clinical evidence items and 0 assertions across 4 variants. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes clinical 0.19, affected pathway 0.84, literature 1.00, genetic association 0.15, somatic mutation 0.97). IntOGen calls it a driver in 7 cohorts (7 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Lymphoid Neoplasm, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
- 1 · What it is
STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors.
- 3 · How drugs use it
No product in this corpus aims at STAT3 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:11364 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P40763 (protein name, function text, keywords and locations (REST API)); CIViC gene STAT3 (2 evidence items, 0 assertions, 4 variants; diseases: Diffuse Large B-cell Lymphoma, T-cell Large Granular Lymphocyte Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000168610 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: ovarian cancer 0.52, acute lymphoblastic leukaemia 0.51, diffuse large B-cell lymphoma 0.54, non-Hodgkin lymphoma 0.75, skin cancer 0.57, lung cancer 0.57 (GraphQL API, CC0)); IntOGen STAT3 (driver in 7 cohorts (Act 7, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Upon activation of IL6ST/gp130 signalling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation. Location: Cytoplasm; Nucleus (UniProt). Locus 17q21.2 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.75 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 3 cohorts (LNM, MLYM, NHL)
- Leukaemia: Open Targets association 0.68 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.57 with lung cancer (MONDO_0008903)
- Ovarian cancer: Open Targets association 0.52 with ovarian cancer (MONDO_0008170)
- Biliary tract cancer: Open Targets association 0.51 with biliary tract cancer (MONDO_0003060)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.19; IntOGen calls it an activating (Act) driver in 7 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: T-cell Large Granular Lymphocyte Leukaemia.
Latest papers
topQuery for this target: (TITLE:"STAT3" OR ABSTRACT:"STAT3" OR TITLE:"signal transducer and activator of transcription 3" OR ABSTRACT:"signal transducer and activator of transcription 3" OR TITLE:"Signal transducer and activator of transcription 3" OR ABSTRACT:"Signal transducer and activator of transcription 3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTBL1XR1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetJAK3
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetIL7R
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFRSF14
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCARD11
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFAIP3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetBCL6
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.